Navigation Links
ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
Date:9/19/2012

BARCELONA, Spain, September 19, 2012 /PRNewswire/ --

ESTEVE's R & D team includes a total of 350 people, 13% of the total global workforce, with the capability to work in all areas of drug discovery and the development of new medicines. This new R&D Center will house 92 scientists focused on two key phases in drug development; (1) The discovery phase, the phase during which new chemical entities are identified that may have the ability to positively change the course of a disease and, (2) the preclinical development phase, which includes performing all the necessary tests to provide the appropriate evidence to allow a new drug to be evaluated in humans.

The transfer to the PCB is an example of ESTEVE's commitment to research, despite the difficult socio-economic environment, as a way to maintain long-term sustainability. One of the keys to this sustainability is the ability to provide innovative solutions to medical needs that have not yet been adequately met. In this new facility, the company expects to increase performance in its R & D activities, improving the overall productivity of the discovery process in the development of new drugs and shorten the time to market.

This is the first alliance of its kind, where a large pharmaceutical company will locate all key competence units for drug discovery and preclinical development in a top quality academic / scientific environment in Spain.

The decision-making process to transfer the R & D team to the PCB took into consideration several factors, the most notable of which is the excellent infrastructure, the advantages of working in a high quality scientific and technical environment and the presence, in a common area, of scholars, researchers, talented young people and groups of entrepreneurs. It represents a further step towards a single model of open innovation in pharmaceutical R & D. ESTEVE's key strategy in R & D is an active policy of creating
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... April 18, 2012 Financial executives in the medical ... and the burden of its related compliance costs will ... according to a survey conducted by KPMG LLP, the ... said their companies are already contemplating actions such as ...
... organiser UBM Live has revealed further details of ... CPhI Southeast Asia (SEA) 2012. Set to debut from 10-12 ... SEA is the first trade show and exhibition of its ... the ASEAN region. CPhI SEA will provide ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:2/27/2015)... Nashville, TN (PRWEB) February 27, 2015 ... Oral Health, has announced a scholarship for rising freshmen ... is Nashville’s leading periodontist office specializing in many periodontal ... , and treatment of gum disease . In ... single $1,000 college scholarship for eligible rising freshmen undergraduate ...
(Date:2/27/2015)... Insight Accelerator Labs has partnered ... development of an in-line urine flow meter platform ... developed in direct response to current high cost ... error margins with potentially grave consequences. The company’s ... provide trending data analysis to signal ICU caregivers ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Mirena IUD ... women who allegedly suffered uterine perforations and other serious ... device continue to move forward in the multicounty litigation ... Liebhard LLP reports. Court records indicate that the ... 24th, following a Conference convened that same day. (In ...
(Date:2/27/2015)... 2015 Over 440,000 patients die annually as ... of two jumbo jet airplanes crashing each day. Now more ... in an effort to do all they can to stay ... Carmona, the 17th U.S. Surgeon General, discusses the importance of ... able to address safety issues to ensure that all our ...
(Date:2/27/2015)... York, NY (PRWEB) February 27, 2015 Ticket ... Tickets for his "Forest Hills Drive Tour Act 3: ... album "2014 Forest Hills Drive" which debuted on the charts ... hip-hop album. In March, this accomplished hip-hop artist will ... in early March and will visit cities such as San ...
Breaking Medicine News(10 mins):Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 3Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 3
... myeloma patients are better equipped to halt progression of this ... stem cell transplant, according to a study co-authored by a ... Institute. The study, published in the New England ... the risk of progressive myeloma or death for the stem ...
... 15 (HealthDay News) -- Researchers have identified gene variants ... say their findings could help identify patients who would ... the University of California-Los Angeles, say their findings also ... disease is a progressive movement disorder marked by tremor, ...
... , TUESDAY, May 15 (HealthDay News) -- Asthma ... million adults (8.2 percent) suffering from the disorder in 2010, ... for Disease Control and Prevention. The CDC analysis also ... adults have been diagnosed with the illness at some point ...
... DETROIT An increasingly common and safer type of surgery ... for older, sicker and poorer patients who are uninsured or ... to a new study by researchers at Henry Ford Hospital. ... the diseased portion of a cancerous kidney, leaving the unaffected ...
... prostate cancer patients may not be getting the same ... first-of-its-kind study by researchers at Henry Ford Hospital who ... remove diseased prostates. While it is possible that ... results of radical prostatectomy are not as good for ...
... Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ... Challenges Explorations winner, an initiative funded by the Bill ... Ph.D., FAAP, LA BioMed lead investigator and Professor of ... and development research project, titled "Aerosol Delivery of Synthetic ...
Cached Medicine News:Health News:Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant 2Health News:Genes Might Be Key to Parkinson's Spread 2Health News:Asthma Cases Continue to Rise in U.S., Affecting Millions 2Health News:Asthma Cases Continue to Rise in U.S., Affecting Millions 3Health News:Safer kidney cancer surgery under-used for poorer, sicker Medicare, Medicaid patients 2Health News:Quality of care, other issues may cause worse results in black prostate cancer surgery patients 2Health News:LA BioMed receives Grand Challenges Explorations grant 2
Cold light source dual outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
... and most versatile light source Luxtec offers. ... this unique light source allows to use ... instrument or two UltraLite Headlights at the ... white light that is as close to ...
Medicine Products: